百花医药：2025年年审工作正在进行中

Core Viewpoint - Baihua Pharmaceutical (600721) is actively enhancing its competitive advantage in the pharmaceutical CRO and related fields, with a focus on optimizing business layout and accelerating customer expansion for high-quality development by 2026 [1] Group 1 - The company is currently conducting its annual audit work for 2025 [1] - Baihua Pharmaceutical plans to strengthen its competitive edge in the pharmaceutical CRO sector and related areas [1] - The company emphasizes the importance of technological innovation and business optimization in its future strategy [1] Group 2 - Baihua Pharmaceutical will continue to promote high-quality development and customer expansion efforts [1] - Investors are encouraged to follow the company's periodic reports for more detailed information [1] - The designated media for the company's information disclosure includes the Shanghai Stock Exchange website and specific financial newspapers [1]